Skip to main content

WAO Immunotherapy and Biologics Online Monograph

Edited by: Ruby Pawankar and Lanny Rosenwasser

An article collection in: World Allergy Organization Journal

The World Allergy Organization Immunotherapy and Biologics Online Monograph comprises thematic state-of-the-art reviews inspired by the deliberations at the WAO Immunotherapy and Biologics Symposium 2013. These reviews highlight the cutting edge advances, future directions, and unmet needs in immunotherapy and biologics and personalized medicine for the diagnosis and treatment of allergic diseases and asthma. With the growing burden of allergic diseases and the increasing evidence of the complexity, severity, and phenotypes of these diseases, newer diagnostic tools and more precise targeted therapies are the need of the hour to meet the growing challenge in the delivery of optimal treatment to patients. This monograph will provide readers with updated knowledge on a wide range of topics, from understanding the fundamentals of the new diagnostic tools and therapies to the use of personalized medicine, sublingual immunotherapy, and other forms of immunotherapy in development.

Support for the dissemination of this monograph is provided by the following sponsors: Circassia, Boehringer-Ingleheim, and ORA Inc. All articles have undergone the journal's standard peer-review process.

  1. Food allergy is a major public health problem affecting nearly 10 % of children in most industrialized countries. Unfortunately, there are no effective therapies for food allergy, relegating patients to simply...

    Authors: Dale T. Umetsu, Rima Rachid and Lynda C. Schneider
    Citation: World Allergy Organization Journal 2015 8:70
  2. Gold Standard allergen-specific immunotherapy is associated with low efficacy because it requires either many subcutaneous injections of allergen or even more numerous sublingual allergen administrations to ac...

    Authors: Gabriela Senti and Thomas M Kündig
    Citation: World Allergy Organization Journal 2015 8:47
  3. IgE-mediated food allergy is a potentially life-threatening allergic disease with an increase in prevalence in developed countries over the past 15 years. Currently, there are no approved forms of therapy and ...

    Authors: Uyenphuong H Le and A Wesley Burks
    Citation: World Allergy Organization Journal 2014 7:82
  4. Airway inflammation is considered to be the primary component contributing to the heterogeneity and severity of airway disorders. Therapeutic efficacies of diverse novel biologics targeting the inflammatory pa...

    Authors: Manali Mukherjee, Roma Sehmi and Parameswaran Nair
    Citation: World Allergy Organization Journal 2014 7:81
  5. Most Latin-American countries use subcutaneous immunotherapy (SCIT) extracts from the United States and Europe and sublingual immunotherapy (SLIT) from Europe, with the exception of Argentina, Brazil, Cuba and...

    Authors: Alexander Diaz Rodriguez, Alexis Labrada Rosado, Raúl Lázaro Castro Almarales and Mirta Álvarez Castelló
    Citation: World Allergy Organization Journal 2014 7:72
  6. Synthetic peptide immuno-regulatory epitopes (SPIRE) represent a new class of therapeutics for allergen immunotherapy that offer the potential to suppress the IgE-mediated allergic disease process through indu...

    Authors: Peter Socrates Creticos
    Citation: World Allergy Organization Journal 2014 7:71
  7. Chronic urticaria is defined as episodic or daily hives lasting for at least 6 weeks and impairs quality of life. Two main subtypes include chronic idiopathic (spontaneous) urticaria and inducible (physical) u...

    Authors: Paul A Greenberger
    Citation: World Allergy Organization Journal 2014 7:70
  8. We recently identified T cell epitopes associated with human allergic responses. In a majority of cases, responses focused on a few immunodominant epitopes which can be predicted on the basis of MHC binding ch...

    Authors: April Frazier, Veronique Schulten, Denise Hinz, Carla Oseroff, John Sidney, Bjoern Peters and Alessandro Sette
    Citation: World Allergy Organization Journal 2014 7:68
  9. Sublingual immunotherapy (SLIT) use in the United States to date has been limited, despite common use and demonstrated efficacy elsewhere in the world. This is largely in part due to lack of FDA-approved SLIT ...

    Authors: Shelby Elenburg and Michael S Blaiss
    Citation: World Allergy Organization Journal 2014 7:67
  10. Allergen-specific immunotherapy (SIT) represents the only curative and specific way for the treatment of allergic diseases, which have reached a pandemic dimension in industrial countries affecting up to 20-30...

    Authors: Mübeccel Akdis
    Citation: World Allergy Organization Journal 2014 7:65
  11. IgE has long been known as a therapeutic target for allergic disease, but the difficulty has been in selecting agents that don't trigger cross linkage of IgE when bound to its high affinity receptor (FceR1) on...

    Authors: Stephen T Holgate
    Citation: World Allergy Organization Journal 2014 7:60